ARCHIVES

New Treatment For CML Could Be Model for Molecular Target-Based Therapeutics

This article is from The Cancer Letter archive.

Vol. 25 No. 47 | December 10, 1999

Download PDF Visit The Full Archive

Related Articles

FDA Lacks Resources To Deal With Onslaught Of New Cancer Drugs, Friedman Tells Agency

August 14, 1992

Republican Congress To Shift Priorities, But Cancer May Get New Opportunities

November 18, 1994

Graalman Objects To Criticism On Contract Competition

April 22, 1977

Biostatistician Thomas Fleming Warns Against Approval of Provenge.

May 4, 2007

Alimta Reduces Risk Of Progression In Patients Aged 70 Years or Older

October 28, 2011

NCI To Pay 34 Percent Of Grants, At 155 Payline; $100 Million for Centers to Fund All Core Grants

January 29, 1988